Tevogen Bio Holdings Inc.
NASDAQ: TVGNW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ryan H. Saadi
- Employees
- 18
- Headquarters
- Warren, United States
- IPO year
- 2024
- Market cap
- $9.3M
- Website
- https://tevogen.com
Loading TVGNW…
Loading profile data…Frequently asked questions about TVGNW
What does Tevogen Bio Holdings Inc. (TVGNW) do?
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company focused on developing ready-to-use, precision T cell therapies. Their research and development efforts span virology, oncology, and neurological conditions. The company's flagship experimental treatment, TVGN 489, is a precision T cell product designed to meet the unmet needs of...
Where does TVGNW trade?
Tevogen Bio Holdings Inc. (TVGNW) trades on the NASDAQ Capital Market.
What sector is TVGNW in?
Tevogen Bio Holdings Inc. (TVGNW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Tevogen Bio Holdings Inc.?
Ryan H. Saadi is the chief executive officer of Tevogen Bio Holdings Inc. (TVGNW).
Where is Tevogen Bio Holdings Inc. headquartered?
Tevogen Bio Holdings Inc. is headquartered in United States.
Does TVGNW pay a dividend?
Tevogen Bio Holdings Inc. (TVGNW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TVGNW go public?
Tevogen Bio Holdings Inc. (TVGNW) completed its initial public offering in 2024.